ROCKWELL AUTOMATION, INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ROCKWELL AUTOMATION, INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Sep 30, 2018 | $1.73B | Nov 9, 2018 |
| FY2018 | Jun 30, 2018 | $1.70B | Nov 9, 2018 |
| FY2018 | Mar 31, 2018 | $1.65B | Nov 9, 2018 |
| FY2018 | Dec 31, 2017 | $1.59B | Nov 9, 2018 |
| FY2018 | Sep 30, 2017 | $1.67B | Nov 9, 2018 |
| FY2018 | Jun 30, 2017 | $1.60B | Nov 9, 2018 |
| FY2018 | Mar 31, 2017 | $1.55B | Nov 9, 2018 |
| FY2018 | Dec 31, 2016 | $1.49B | Nov 9, 2018 |
| FY2018 | Sep 30, 2016 | $5.88B | Nov 9, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $8.34B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $8.26B | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $9.06B | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | $7.76B | Nov 12, 2024 |
| FY2023 | Sep 30, 2021 | $7.00B | Nov 8, 2023 |
| FY2020 | Sep 30, 2020 | $1.57B | Nov 10, 2020 |
| FY2020 | Jun 30, 2020 | $1.39B | Nov 10, 2020 |
| FY2020 | Mar 31, 2020 | $1.68B | Nov 10, 2020 |
| FY2020 | Dec 31, 2019 | $1.68B | Nov 10, 2020 |
| FY2020 | Sep 30, 2019 | $1.73B | Nov 10, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | $1.67B | Nov 15, 2017 |
| FY2017 | Jun 30, 2017 | $1.60B | Nov 15, 2017 |
| FY2017 | Mar 31, 2017 | $1.55B | Nov 15, 2017 |
| FY2017 | Dec 31, 2016 | $1.49B | Nov 15, 2017 |
| FY2017 | Sep 30, 2016 | $1.54B | Nov 15, 2017 |
| FY2017 | Jun 30, 2016 | $1.47B | Nov 15, 2017 |
| FY2017 | Mar 31, 2016 | $1.44B | Nov 15, 2017 |
| FY2017 | Dec 31, 2015 | $1.43B | Nov 15, 2017 |
| FY2016 | Sep 30, 2015 | $1.61B | Nov 15, 2016 |
| FY2016 | Jun 30, 2015 | $1.58B | Nov 15, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $4.02B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $3.85B | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $4.42B | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | $3.10B | Nov 12, 2024 |
| FY2023 | Sep 30, 2021 | $2.90B | Nov 8, 2023 |
| FY2020 | Sep 30, 2020 | $639.30M | Nov 10, 2020 |
| FY2020 | Jun 30, 2020 | $554.20M | Nov 10, 2020 |
| FY2020 | Mar 31, 2020 | $698.80M | Nov 10, 2020 |
| FY2020 | Dec 31, 2019 | $702.90M | Nov 10, 2020 |
| FY2020 | Sep 30, 2019 | $722.90M | Nov 10, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $869.00M | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $953.00M | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $1.39B | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | $932.20M | Nov 12, 2024 |
| FY2023 | Sep 30, 2021 | $1.36B | Nov 8, 2023 |
| FY2020 | Sep 30, 2020 | $262.70M | Nov 10, 2020 |
| FY2020 | Jun 30, 2020 | $317.80M | Nov 10, 2020 |
| FY2020 | Mar 31, 2020 | $132.20M | Nov 10, 2020 |
| FY2020 | Dec 31, 2019 | $310.70M | Nov 10, 2020 |
| FY2020 | Sep 30, 2019 | $8.10M | Nov 10, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.70B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $1.60B | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $1.93B | Nov 12, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $679.00M | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $658.00M | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $706.00M | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | $440.90M | Nov 12, 2024 |
| FY2023 | Sep 30, 2021 | $422.50M | Nov 8, 2023 |
| FY2022 | Sep 30, 2020 | $371.50M | Nov 8, 2022 |
| FY2021 | Sep 30, 2019 | $378.90M | Nov 9, 2021 |
| FY2020 | Sep 30, 2018 | $371.80M | Nov 10, 2020 |
| FY2019 | Sep 30, 2017 | $348.20M | Nov 12, 2019 |
| FY2018 | Sep 30, 2016 | $319.30M | Nov 9, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.91B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $2.00B | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $2.02B | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | $1.77B | Nov 12, 2024 |
| FY2023 | Sep 30, 2021 | $1.68B | Nov 8, 2023 |
| FY2022 | Sep 30, 2020 | $1.48B | Nov 8, 2022 |
| FY2021 | Sep 30, 2019 | $1.54B | Nov 9, 2021 |
| FY2020 | Sep 30, 2018 | $1.59B | Nov 10, 2020 |
| FY2019 | Sep 30, 2017 | $1.56B | Nov 12, 2019 |
| FY2018 | Sep 30, 2016 | $1.47B | Nov 9, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.54B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $864.00M | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $1.37B | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | $823.10M | Nov 12, 2024 |
| FY2023 | Sep 30, 2021 | $1.26B | Nov 8, 2023 |
| FY2022 | Sep 30, 2020 | $1.12B | Nov 8, 2022 |
| FY2021 | Sep 30, 2019 | $1.18B | Nov 9, 2021 |
| FY2020 | Sep 30, 2018 | $1.30B | Nov 10, 2020 |
| FY2019 | Sep 30, 2017 | $1.03B | Nov 12, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Sep 30, 2023 | $160.50M | Nov 8, 2023 |
| FY2023 | Sep 30, 2022 | $141.10M | Nov 8, 2023 |
| FY2023 | Sep 30, 2021 | $120.30M | Nov 8, 2023 |
| FY2022 | Sep 30, 2020 | $113.90M | Nov 8, 2022 |
| FY2021 | Sep 30, 2019 | $132.80M | Nov 9, 2021 |
| FY2020 | Sep 30, 2018 | $125.50M | Nov 10, 2020 |
| FY2019 | Sep 30, 2017 | $141.70M | Nov 12, 2019 |
| FY2018 | Sep 30, 2016 | $116.90M | Nov 9, 2018 |
| FY2017 | Sep 30, 2015 | $122.90M | Nov 15, 2017 |
| FY2016 | Sep 30, 2014 | $141.00M | Nov 15, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $11.22B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $11.23B | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $11.30B | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | $10.76B | Nov 12, 2024 |
| FY2023 | Sep 30, 2021 | $10.70B | Nov 8, 2023 |
| FY2022 | Sep 30, 2020 | $7.26B | Nov 8, 2022 |
| FY2021 | Sep 30, 2019 | $6.11B | Nov 9, 2021 |
| FY2020 | Sep 30, 2018 | $6.26B | Nov 10, 2020 |
| FY2019 | Sep 30, 2017 | $7.16B | Nov 12, 2019 |
| FY2018 | Sep 30, 2016 | $7.10B | Nov 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $3.65B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $3.50B | Nov 12, 2025 |
| FY2024 | Sep 30, 2023 | $3.56B | Nov 12, 2024 |
| FY2023 | Sep 30, 2022 | $2.73B | Nov 8, 2023 |
| FY2022 | Sep 30, 2021 | $2.39B | Nov 8, 2022 |
| FY2021 | Sep 30, 2020 | $1.03B | Nov 9, 2021 |
| FY2020 | Sep 30, 2019 | $404.20M | Nov 10, 2020 |
| FY2019 | Sep 30, 2018 | $1.62B | Nov 12, 2019 |
| FY2019 | Sep 30, 2017 | $2.66B | Nov 12, 2019 |
| FY2019 | Sep 30, 2016 | $1.99B | Nov 12, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $3.84B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $3.99B | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $3.53B | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | $3.52B | Nov 12, 2024 |
| FY2023 | Sep 30, 2021 | $3.63B | Nov 8, 2023 |
| FY2021 | Sep 30, 2020 | $1.65B | Nov 9, 2021 |
| FY2021 | Sep 30, 2019 | $1.07B | Nov 9, 2021 |
| FY2020 | Sep 30, 2018 | $1.08B | Nov 10, 2020 |
| FY2019 | Sep 30, 2017 | $1.08B | Nov 12, 2019 |
| FY2018 | Sep 30, 2016 | $1.07B | Nov 9, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $5.42B | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $9.64B | Nov 12, 2025 |
| FY2024 | Sep 30, 2023 | $9.26B | Nov 12, 2024 |
| FY2023 | Sep 30, 2022 | $8.41B | Nov 8, 2023 |
| FY2022 | Sep 30, 2021 | $8.00B | Nov 8, 2022 |
| FY2021 | Sep 30, 2020 | $7.14B | Nov 9, 2021 |
| FY2020 | Sep 30, 2019 | $6.44B | Nov 10, 2020 |
| FY2019 | Oct 1, 2018 | $6.20B | Nov 12, 2019 |
| FY2019 | Sep 30, 2018 | $6.20B | Nov 12, 2019 |
| FY2018 | Sep 30, 2017 | $6.10B | Nov 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $468.00M | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | $471.00M | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | $1.07B | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | $490.70M | Nov 12, 2024 |
| FY2023 | Sep 30, 2021 | $662.20M | Nov 8, 2023 |
| FY2022 | Sep 30, 2020 | $704.60M | Nov 8, 2022 |
| FY2021 | Sep 30, 2019 | $1.02B | Nov 9, 2021 |
| FY2020 | Sep 30, 2018 | $618.80M | Nov 10, 2020 |
| FY2018 | Sep 30, 2017 | $1.41B | Nov 9, 2018 |
| FY2018 | Sep 30, 2016 | $1.53B | Nov 9, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Sep 30, 2020 | $1.97B | Nov 10, 2020 |
| FY2020 | Sep 30, 2019 | $2.26B | Nov 10, 2020 |
| FY2019 | Sep 30, 2018 | $1.23B | Nov 12, 2019 |
| FY2018 | Sep 30, 2017 | $1.49B | Nov 9, 2018 |
| FY2017 | Sep 30, 2016 | $1.52B | Nov 15, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 7 | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | 8 | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | 12 | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | 8 | Nov 12, 2024 |
| FY2023 | Sep 30, 2021 | 11 | Nov 8, 2023 |
| FY2020 | Sep 30, 2020 | 2 | Nov 10, 2020 |
| FY2020 | Jun 30, 2020 | 2 | Nov 10, 2020 |
| FY2020 | Mar 31, 2020 | 1 | Nov 10, 2020 |
| FY2020 | Dec 31, 2019 | 2 | Nov 10, 2020 |
| FY2020 | Sep 30, 2019 | 0 | Nov 10, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 7 | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | 8 | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | 11 | Nov 12, 2025 |
| FY2024 | Sep 30, 2022 | 7 | Nov 12, 2024 |
| FY2023 | Sep 30, 2021 | 11 | Nov 8, 2023 |
| FY2020 | Sep 30, 2020 | 2 | Nov 10, 2020 |
| FY2020 | Jun 30, 2020 | 2 | Nov 10, 2020 |
| FY2020 | Mar 31, 2020 | 1 | Nov 10, 2020 |
| FY2020 | Dec 31, 2019 | 2 | Nov 10, 2020 |
| FY2020 | Sep 30, 2019 | 0 | Nov 10, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 112.40M | Nov 12, 2025 |
| FY2025 | Sep 30, 2024 | 113.10M | Nov 12, 2025 |
| FY2025 | Sep 30, 2023 | 114.80M | Nov 12, 2025 |
| FY2025 | Sep 30, 2022 | 115.20M | Nov 12, 2025 |
| FY2024 | Sep 30, 2021 | 116.00M | Nov 12, 2024 |
| FY2023 | Sep 30, 2020 | 116.20M | Nov 8, 2023 |
| FY2022 | Sep 30, 2019 | 115.70M | Nov 8, 2022 |
| FY2021 | Sep 30, 2018 | 121.00M | Nov 9, 2021 |
| FY2020 | Sep 30, 2017 | 128.40M | Nov 10, 2020 |
| FY2019 | Sep 30, 2016 | 128.50M | Nov 12, 2019 |